Explore the Agenda
9:00 am Registration & Morning Coffee
9:30 am Workshop A
Fixing Phage’s Biggest Bottleneck: Building Sustainable Investment, Business Models & Reimbursement Pathways
The World Health Organization (WHO) warns that antimicrobial resistance (AMR) could cause 39 million deaths over the next 25 years, with annual deaths potentially exceeding 10 million by 2050 and costing the global economy up to $1 trillion annually. Despite growing urgency, phage therapy, one of the most promising solutions to AMR, continues to face a persistent investment drought, compounded by the lack of viable reimbursement and commercial models to sustain long-term innovation.
Join this interactive workshop to explore how developers and investors are breaking through these barriers to unlock scalable, sustainable phage therapy development by addressing:
- Why investment, business model uncertainty and lack of reimbursement pathways collectively remain the biggest bottlenecks slowing phage progress
- Lessons from biotech leaders proving commercial viability through creative partnerships, diversified pipelines and value-based frameworks
- How push and pull incentives can catalyze early investment, and what structural changes are needed to make them sustainable
- What evidence, milestones and health-economic data are needed to convince regulators and payers to act faster than bacteria can evolve
12:30 pm Lunch Break & Networking
1:30 pm Workshop B
Advancing Phage Therapeutics into Late-Stage Clinical Trials: Bridging Translational Gaps to Enable Regulatory & Commercial Success
As early clinical results generate growing enthusiasm, the phage field now faces the critical hurdle of translating promising preclinical and early-phase data into robust, latestage clinical trials. Designing studies that satisfy regulatory expectations, demonstrate reproducible efficacy, and attract sustainable investment remains a defining challenge for the community.
Join this workshop to examine how leading developers are overcoming the translational,
operational, and strategic barriers limiting late-stage progress:
- How can trial design, patient selection, and endpoints be optimized to demonstrateconsistent efficacy across diverse infections and populations?
- What regulatory and manufacturing considerations must be addressed to align with IND/CTA and pivotal trial requirements?
- How can partnerships, data generation, and funding models evolve to de-risk and accelerate late-stage development?